Key Takeaways:Musely has been growing its revenue by an average of 50% year over year and has served over 1.2 million patients.CVF’s terms were more favorable than a standard bank loan and far less costly than a dilutive equity round.Musely has been remarkably capital efficient, raising roughly $40 million from investors.Telemedicine platform Musely raised more than $360 million in non-dilutive capital from General Catalyst Customer Value Fund (CVF).WHO: Founded in 2019, Musely has built a thriving community of over 1 million patients, supported by board-certified physicians and pharmacists who deliver personalized treatments straight to patients' doors. Its vertically integrated prescription telemedicine system unites diagnosis, compounding, and delivery under one roof. Two pharmacies built from scratch at 40,000 square feet each, proprietary software developed in-house because the existing pharmacy tech industry was still running on outdated systems, and mini assembly lines designed for personalized prescription batching. Every bottle is physically signed off by a licensed pharmacist, and none of that complexity is incidental. WHY: CVF’s terms were more favorable than a standard bank loan and far less costly than a dilutive equity round, solving the cost of acquisition. The deal provides Musely with a capital war chest to support its customer growth, funding sales, marketing, and other customer acquisition efforts.IN THEIR OWN WORDS: Acquiring new customers for DTC brands like Musely can be very costly, Jack Jia, Musely founder, explained to Techcrunch.